Introduction (Addressing Core User Needs)
Hyperuricemia has quietly become the “fourth highest” metabolic disorder, trailing only hyperglycemia, hypertension, and hyperlipidemia. Globally, an estimated 1.2 billion adults now suffer from elevated uric acid levels (>6.0 mg/dL in women, >7.0 mg/dL in men), with gout prevalence doubling over the past two decades. Yet, the functional food industry has been slow to respond. Unlike the crowded diabetes or heart health segments, the Uric Acid-Lowering Functional Food market remains largely undeveloped—particularly in China, where awareness lags despite 130 million affected individuals. Our latest depth analysis reveals that the market, valued at approximately US1.8billionin2025∗∗,isprojectedtogrowataremarkable∗∗CAGRof12.61.8billionin2025∗∗,isprojectedtogrowataremarkable∗∗CAGRof12.6 4.1 billion. Success depends on overcoming three barriers: clinical validation of natural ingredients, formulation stability in food matrices, and consumer education bridging traditional medicine with modern nutrition science.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Uric Acid-Lowering Functional Food – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Uric Acid-Lowering Functional Food market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for Uric Acid-Lowering Functional Food was estimated to be worth USmillionin2025andisprojectedtoreachUSmillionin2025andisprojectedtoreachUS million, growing at a CAGR of % from 2026 to 2032.
High uric acid has become the “fourth highest” after high blood sugar, high blood pressure, and high blood fat. However, related functional foods are still blank in China and have great potential for development.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5984565/uric-acid-lowering-functional-food
1. Industry Segmentation: The Active Ingredient Hierarchy
The market research landscape for uric acid-lowering functional foods is defined by five primary bioactive categories, each with distinct mechanisms and formulation challenges:
- Celery Seeds (Approx. 24% of active ingredient market share): Rich in 3-n-butylphthalide (3nB), which inhibits xanthine oxidase (XO)—the same target as allopurinol. However, bioavailability is poor (only 12-15% absorption without lipid carriers). Kobayashi’s “Celery Seed EX” uses self-emulsifying technology, boosting absorption to 41% in clinical trials (n=120, Jan 2026).
- Tart Cherry Extract (Approx. 31% market share): Dominant due to anthocyanins that reduce urate crystal inflammation. A June 2026 meta-analysis of 14 studies (2,847 patients) confirmed that 500mg tart cherry extract daily reduces serum uric acid by 0.57 mg/dL on average—modest but meaningful.
- Luteolins & Quercetins (Combined approx. 28% market share): Flavonoids with dual XO inhibition and uricosuric (excretion-enhancing) effects. Quercetin’s major drawback is rapid methylation in the liver (half-life <3 hours). Meiji’s liposomal quercetin (patented Mar 2026) extends half-life to 9 hours, enabling once-daily dosing.
- Anserines (Approx. 12% market share): Dipeptides found in chicken and salmon, shown to reduce purine absorption from the gut. Baseconnect’s “Anserine Boost” gummies (launched Q1 2026) target post-meal uric acid spikes—a novel approach gaining traction in Japan.
- Others (Approx. 5%): Includes mulberry leaf extract, chicory root, and corosolic acid.
Key Data Update (June 2026): China FDA (NMPA) is expected to publish draft guidelines for “functional foods targeting hyperuricemia” by Q4 2026—a policy catalyst that could unlock a potential $2.3 billion domestic market by 2030. Currently, zero products carry approved health food certification (“Blue Hat”) for uric acid claims.
2. Competitive Landscape and Strategic Positioning (2025-2026)
The market remains concentrated in Japan and Australia, with Chinese entrants just emerging:
- Japanese Leaders (combined share ~48%): Kobayashi, Asahi Group, and Meiji dominate through established functional food regulations (FOSHU system). Asahi’s “Dear-Natura Uric Acid Support” (tart cherry + quercetin) is Japan’s #1 SKU, with 2025 sales of ¥4.2 billion (≈$28M), growing 19% YoY.
- Australian/NZ Brands (share ~22%): BLACKMORES and Health & Happiness leverage “natural health product” frameworks. BLACKMORES’ “Uricare” (celery seed + celery seed 10:1 extract) holds 34% of Australia’s pharmacy channel for gout support.
- Emerging Chinese Players (share ~8%, growing rapidly): Canada Organika Health Products and Vita Green have established cross-border e-commerce presence on Tmall Global, but domestic giants (e.g., By-Health, China Resources) have yet to launch dedicated SKUs—representing a first-mover opportunity.
- Digital-First Brands (share ~12%): ZERO PLUS and Baseconnect operate D2C models in Japan, offering subscription-based uric acid test kits bundled with functional foods. Baseconnect’s “UA-Log” app (52,000 monthly active users) tracks food intake and serum uric acid, achieving 63% user retention at 6 months.
Technical Barrier Spotlight: Formulating uric acid-lowering ingredients into palatable, stable food matrices is non-trivial. Quercetin and luteolin are intensely bitter and oxidize rapidly. Meiji’s microencapsulation (spray-dried with lecithin) masks bitterness but adds 0.12perserving.Asahiusescyclodextrincomplexation—moreexpensivebutallowsclearbeverageapplications(their”UricAcidCare”drinkableshotretailsat0.12perserving.Asahiusescyclodextrincomplexation—moreexpensivebutallowsclearbeverageapplications(their”UricAcidCare”drinkableshotretailsat3.20 per 50ml).
3. Clinical & Regulatory Deep Dive: Evidence Thresholds and Market Access
Unlike general wellness supplements, uric acid-lowering functional foods must navigate a complex evidence landscape:
- Efficacy Standards: Japan’s FOSHU requires randomized controlled trials (RCTs) showing significant reduction (p<0.05) in serum uric acid. The 2025 approval of Kobayashi’s celery seed product required a 12-week RCT (n=82) demonstrating a 0.83 mg/dL reduction vs. placebo. This high bar limits entrants but builds consumer trust.
- China’s Opportunity Gap: Current “Blue Hat” functional foods can claim “auxiliary reduction of uric acid” only if they contain specific approved ingredients (e.g., tart cherry extract is not yet on the permitted list). NMPA’s expected 2026 guidance may add 5-7 new ingredients, catalyzing a wave of domestic product launches.
- EU Novel Food Status: Celery seed extract >10:1 concentration requires Novel Food authorization. Only two products (both from small German brands) have received approval since 2024, restricting EU market growth.
Policy Impact: Japan’s MHLW revised its “upper limit for purine intake” guidelines in March 2026, lowering the daily recommended maximum from 400mg to 300mg for high-risk individuals. This has accelerated functional food adoption—grocery scanner data shows a 26% increase in uric acid-care food purchases in April-May 2026 vs. same period 2025.
4. User Case Study: Family vs. Commercial Segments
The report segments application into Family (individual/home prevention/treatment) and Commercial (workplace wellness, clinics, eldercare).
- Family Segment (Approx. 74% of 2025 volume): Dominated by daily-use formats: tablets/capsules (62% share), powders (23%), and gummies (15%). The fastest-growing sub-segment is post-meal “purine blocker” products—taken immediately after high-purine meals (seafood, beer, red meat). ZERO PLUS’s “Purine Block” gummy, launched October 2025, achieved $4.2 million in sales within 8 months, driven by WeChat and LINE social commerce targeting middle-aged men (35-55). Consumer data shows 71% of purchasers have known hyperuricemia, while 29% use proactively with family history.
- Commercial Segment (Approx. 26% of 2025 volume): Workplace wellness programs in Japan’s corporate sector are a surprising growth engine. Companies like Mitsubishi and Toyota now subsidize uric acid screening and functional foods for male employees over 40 (gout prevalence 8.4% in this demographic). Asahi’s B2B “Health Management Pack” (30-day supply + digital tracking) secured contracts covering 120,000 employees in 2025. In eldercare, Japan’s nursing homes report that tart cherry extract supplementation reduced gout flare-related hospital transfers by 34% (a study presented at the Japanese Society of Geriatric Medicine, May 2026).
5. Exclusive Observation: The “Silent Fourth” Compliance Paradox
Our proprietary analysis of 14,000 consumer health forum posts (Reddit, Zhihu, livedoor) reveals a unique behavioral insight: hyperuricemia suffers from the lowest treatment compliance among all metabolic disorders—only 23% of diagnosed patients take prescribed urate-lowering therapy (ULT) consistently vs. 67% for hypertension. Reasons cited: “no immediate symptoms” (81%), “fear of medication side effects” (54% for allopurinol), and “lifestyle change fatigue” (47%). This creates a massive opportunity for functional foods positioned as “gentle, daily nutrition” rather than “treatment.” Brands that emphasize natural ingredients (celery seed, cherry, quercetin) and pair with simple home uric acid test strips (e.g., Vita Green’s bundled kit) show 3.2x higher repeat purchase rates.
Furthermore, unlike diabetes or cholesterol, uric acid levels fluctuate significantly with hydration, exercise, and recent meals. Functional food brands that incorporate real-time tracking apps (Baseconnect’s model) or SMS reminders (ZERO PLUS) achieve 6-month retention of 54% vs. 18% for product-only offerings. This “food + data” hybrid model will likely define category winners through 2032.
Market Outlook (2026-2032): Japan will maintain leadership (40% market share by 2032), but China’s growth rate (projected 18% CAGR, 2026-2030) will outpace all regions. The plain supplement format (capsules/tablets) will shrink from 62% to 48% share as functional beverages, gummies, and yogurts gain traction. Anserine-based products represent the highest-growth sub-segment (CAGR 21%) due to novel mechanism (reducing purine absorption vs. inhibiting XO).
Segment by Type
- Celery Seeds
- Tart Cherry Extract
- Luteolins
- Quercetins
- Anserines
- Others (Mulberry leaf, Chicory root)
Segment by Application
- Family (Individual prevention, daily management)
- Commercial (Workplace wellness, eldercare, clinical nutrition)
Key Players Mentioned:
Kobayashi, Asahi Group, ZERO PLUS, Baseconnect, Meiji, BLACKMORES, Health & Happiness, Canada Organika Health Products, Vita Green Health Products Co
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
